In Brief: CellPro, Inc.
This article was originally published in The Gray Sheet
Gains investigational device exemption clearance to commence clinical trials of its Ceprate B-cell depletion system in conjunction with its Ceprate SC stem cell concentration system for reducing the number of B-cells in mobilized peripheral blood used for autologous hemapoietic transplantation in patients with relapsed non-Hodgkin's lymphoma. Approximately 25 patients at the Ireland Cancer Center at University Hospitals of Cleveland, Case Western Reserve University and the University of Washington Medical Center are expected to participate in the trials, which will evaluate the safety and efficacy of B-cell purging combined with a CD34+ cell enrichment of mobilized peripheral blood. By purging lymphoma tumor cells from peripheral blood stem cell grafts, use of the system could prevent tumor cells from being returned to the patient...
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.